AlphAIAlphAI — Financial news for AI agents
stocktitan.net$LIVN

LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova reported Q3 2026 revenue of $393.1M, up 9.9%, and raised full-year 2026 revenue guidance to 9-10% growth. Adjusted EPS was $1.23, and the company expects adjusted EPS of $4.30-$4.40 for 2026. LivaNova also achieved a production milestone for oxygenators and new CPT codes for sleep apnea therapy.

Original reporting
stocktitan.net
Published Nov 4, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LIVN
Bullish
high confidence
Mentioned
$LIVN
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LIVNBullishHigh
01

Why it matters

The earnings beat and raised guidance may attract growth‑oriented investors.

02

Market read

First‑report earnings and guidance lift for a mid‑cap med‑tech stock.

03

What to watch

Potential regulatory or reimbursement risks for new CPT codes could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

LivaNova is a global medical‑technology firm focusing on cardiopulmonary and neuromodulation devices.

Company-level read

Ticker impact

$LIVNBullishHigh confidence
Context

LivaNova reported Q3 2026 results and raised full-year revenue and EPS guidance.

Expected impact

likely upside as market prices in raised guidance

Evidence & confidence

Revenue grew 9.9% YoY and guidance was increased, indicating improved performance.

Market effects

Sector

Positive signal for medical technology and neuromodulation sectors.

Regional

May boost European and U.S. med‑tech equities.

Global

Limited to healthcare investors, no broad market effect.

Counterpoint

What could challenge this read

If guidance upgrades are already priced in, the stock could face a pull‑back.

Key entities

  • Executive
    Vladimir Makatsaria

    CEO of LivaNova, quoted on performance.

Read at source← All news

StoryLivaNova posts Q3 2026 earnings beat and lifts full‑year revenue and EPS guidance

Also covered by

6 outlets

Related articles

$LIVNMed

LivaNova PLC (LIVN) (Q3 2026) Earnings Call Highlights: Double-Digit Growth Fuels

LivaNova PLC (LIVN) reported Q3 2026 earnings with adjusted free cash flow declining to $56M from $62M YoY. SG&A expenses rose to $136M from $123M, and a $400M payment shifted to Q4, creating cash flow uncertainty. The company expects 1% FX tailwind but $5M tariff headwinds. Cardiopulmonary growth remains strong, with double-digit increases, and the next-gen oxygenator launch is on track for 2028.

finance.yahoo.com
$LIVNMed

LivaNova PLC Q3 2026 Earnings Call Summary

LivaNova PLC raised its full-year 2026 revenue guidance to 9-10% growth and adjusted EPS to $4.40-$4.50. Growth was driven by record Essence heart-lung machine placements, epilepsy volume growth, and reduced discounting. The company plans to enter the obstructive sleep apnea (OSA) market in 2027 and expects double-digit capacity expansion in 2027 due to new manufacturing lines. Management highlighted strong demand for oxygenators and strategic initiatives to support future growth.

finance.yahoo.com
$LIVNMed

Mizuho raises Livanova stock price target on Essenz placements

Mizuho raised its price target for Livanova (LIVN) to $115 from $95, citing strong U.S. Cardiopulmonary segment growth and Essenz placements. The stock has risen 48% in the past year, trading at $96.59. Livanova reported Q3 2026 earnings of $1.23 per share, beating estimates, and raised its full-year outlook. Jefferies also increased its price target to $120.

investing.com
$LIVNHighAI 8/10

Jefferies raises Livanova stock price target to $120 on guidance

Jefferies increased its price target for LivaNova (NASDAQ:LIVN) to $120 from $100, maintaining a Buy rating. The company reported Q3 sales of $393M, up 10%, and EPS of $1.23, up 20%, both beating estimates. LivaNova raised its full-year sales growth guidance to 9-10% and EPS guidance to $4.40-$4.50. The stock has a market cap of $5.33B and a PEG ratio of 0.12, according to InvestingPro.

investing.com